Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves : The TRANSIT International Project. / Testa, Luca; Agnifili, Mauro; Van Mieghem, Nicolas M.; Tchétché, Didier; Asgar, Anita W.; De Backer, Ole; Latib, Azeem; Reimers, Bernhard; Stefanini, Giulio; Trani, Carlo; Colombo, Antonio; Giannini, Francesco; Bartorelli, Antonio; Wojakowski, Wojtek; Dabrowski, MacIej; Jagielak, Dariusz; Banning, Adrian P.; Kharbanda, Rajesh; Moreno, Raul; Schofer, Joachim; Van Royen, Niels; Pinto, Duane; Serra, Antoni; Segev, Amit; Giordano, Arturo; Brambilla, Nedy; Popolo Rubbio, Antonio; Casenghi, Matteo; Oreglia, Jacopo; De Marco, Federico; Tanja, Rudolph; McCabe, James M.; Abizaid, Alexander; Voskuil, Michiel; Teles, Rui; Biondi Zoccai, Giuseppe; Bianchi, Giovanni; Sondergaard, Lars; Bedogni, Francesco.
I: Circulation: Cardiovascular Interventions, Bind 14, Nr. 6, e010440, 2021, s. 628-638.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves
T2 - The TRANSIT International Project
AU - Testa, Luca
AU - Agnifili, Mauro
AU - Van Mieghem, Nicolas M.
AU - Tchétché, Didier
AU - Asgar, Anita W.
AU - De Backer, Ole
AU - Latib, Azeem
AU - Reimers, Bernhard
AU - Stefanini, Giulio
AU - Trani, Carlo
AU - Colombo, Antonio
AU - Giannini, Francesco
AU - Bartorelli, Antonio
AU - Wojakowski, Wojtek
AU - Dabrowski, MacIej
AU - Jagielak, Dariusz
AU - Banning, Adrian P.
AU - Kharbanda, Rajesh
AU - Moreno, Raul
AU - Schofer, Joachim
AU - Van Royen, Niels
AU - Pinto, Duane
AU - Serra, Antoni
AU - Segev, Amit
AU - Giordano, Arturo
AU - Brambilla, Nedy
AU - Popolo Rubbio, Antonio
AU - Casenghi, Matteo
AU - Oreglia, Jacopo
AU - De Marco, Federico
AU - Tanja, Rudolph
AU - McCabe, James M.
AU - Abizaid, Alexander
AU - Voskuil, Michiel
AU - Teles, Rui
AU - Biondi Zoccai, Giuseppe
AU - Bianchi, Giovanni
AU - Sondergaard, Lars
AU - Bedogni, Francesco
N1 - Publisher Copyright: © 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Background: Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in the treatment of patients with severe aortic stenosis. However, the durability of bioprostheses is still a matter of concern, and little is known about the management of degenerated TAV. We sought to evaluate the outcomes of patients with a degenerated TAV treated by means of a second TAVR. Methods: The TRANSIT is an international registry that included cases of degenerated TAVR from 28 centers. Among around 40 000 patients treated with TAVR in the participating centers, 172 underwent a second TAVR: 57 (33%) for a mainly stenotic degenerated TAV, 97 (56%) for a mainly regurgitant TAV, and 18 (11%) for a combined degeneration. Overall, the rate of New York Heart Association class III/IV at presentation was 73.5%. Results: Valve Academic Research Consortium 2 device success rate was 79%, as a consequence of residual gradient (14%) or regurgitation (7%). At 1 month, the overall mortality rate was 2.9%, while rates of new hospitalization and New York Heart Association class III/IV were 3.6% and 7%, respectively, without significant difference across the groups. At 1 year, the overall mortality rate was 10%, while rates of new hospitalization and New York Heart Association class III/IV were 7.6% and 5.8%, respectively, without significant difference across the groups. No cases of valve thrombosis were recorded. Conclusions: Selected patients with a degenerated TAV may be safely and successfully treated by means of a second TAVR. This finding is of crucial importance for the adoption of the TAVR technology in a lower risk and younger population.
AB - Background: Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in the treatment of patients with severe aortic stenosis. However, the durability of bioprostheses is still a matter of concern, and little is known about the management of degenerated TAV. We sought to evaluate the outcomes of patients with a degenerated TAV treated by means of a second TAVR. Methods: The TRANSIT is an international registry that included cases of degenerated TAVR from 28 centers. Among around 40 000 patients treated with TAVR in the participating centers, 172 underwent a second TAVR: 57 (33%) for a mainly stenotic degenerated TAV, 97 (56%) for a mainly regurgitant TAV, and 18 (11%) for a combined degeneration. Overall, the rate of New York Heart Association class III/IV at presentation was 73.5%. Results: Valve Academic Research Consortium 2 device success rate was 79%, as a consequence of residual gradient (14%) or regurgitation (7%). At 1 month, the overall mortality rate was 2.9%, while rates of new hospitalization and New York Heart Association class III/IV were 3.6% and 7%, respectively, without significant difference across the groups. At 1 year, the overall mortality rate was 10%, while rates of new hospitalization and New York Heart Association class III/IV were 7.6% and 5.8%, respectively, without significant difference across the groups. No cases of valve thrombosis were recorded. Conclusions: Selected patients with a degenerated TAV may be safely and successfully treated by means of a second TAVR. This finding is of crucial importance for the adoption of the TAVR technology in a lower risk and younger population.
KW - bioprosthesis
KW - heart failure
KW - transcatheter aortic valve replacement
U2 - 10.1161/CIRCINTERVENTIONS.120.010440
DO - 10.1161/CIRCINTERVENTIONS.120.010440
M3 - Journal article
C2 - 34092097
AN - SCOPUS:85108076958
VL - 14
SP - 628
EP - 638
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
SN - 1941-7640
IS - 6
M1 - e010440
ER -
ID: 304058192